Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Lucid Diagnostics Q3 2026 Results: Net Loss of $6.68M, Loss Narrows

Lucid Diagnostics reported a net loss of $6.7 million for the quarter ended September 30, 2026, an improvement from the $10.4 million loss in the prior year period. Total revenue remained flat year-over-year at $1.2 million, while the company significantly reduced its total liabilities from $29.5 million at year-end 2025 to $21.9 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.21.2
Profit before tax-6.7-10.4
Net income-6.7-10.4
EPS (diluted, $ a share)$-0.03$-0.10

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-0.7%
Source

10-Q filed with the SEC, NASDAQ: LUCD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Lucid Diagnostics Inc.: key numbers

Share price
$0.3978Close, Nov 16
Market cap
$82.3M
Shares outstanding
206.98MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Lucid Diagnostics Inc.

All →
8:05 AM ET 8-K
Financial Results

Lucid Diagnostics Financial Results

Lucid Diagnostics reported third quarter 2026 financial results, highlighting the commencement of Medicare reimbursement for its EsoGuard Esophageal DNA Test at a rate of $1,938.01 per test. The company performed 2,871 tests during the quarter and reported record monthly test volume in October following the Medicare coverage milestone.

“Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test. This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth.”

Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer

“Our pursuit of EsoGuard’s enormous clinical and commercial opportunity is now substantially less constrained by external factors. Lucid’s near-term growth now depends almost entirely on our team’s commercial and operational execution. Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity with the urgency and determination it deserves. We are laser-focused on expanding access to EsoGuard for Medicare beneficiaries and translating this early momentum into revenue growth. What has been a marathon is now a sprint.”

Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer
4:35 PM ET 8-K
Capital Raise

Lucid Diagnostics Capital Raise of $15M

Lucid Diagnostics entered into subscription agreements with accredited investors for the private placement of 15,000 shares of newly designated Series C Convertible Preferred Stock. The offering generated aggregate gross proceeds of approximately $15.0 million at a purchase price of $1,000 per share.

Value
$15M
4:31 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Lucid Diagnostics Nasdaq/NYSE Compliance Notice

Lucid Diagnostics Inc. received a deficiency notice from Nasdaq on October 12, 2026, because its common stock closing bid price fell below the $1.00 minimum requirement for 30 consecutive business days. The company has 180 calendar days, until April 12, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days.

Counterparty
Nasdaq
Term
180 days
9:07 AM ET 8-K
Business Update

Lucid Diagnostics Business Update

Lucid Diagnostics announced progress across three regulatory and reimbursement pathways for its EsoGuard and EsoCheck products, including a Medicare Advisory Panel recommendation to maintain its current payment basis. Additionally, the AMA approved a new Category III CPT code for EsoCheck procedures, and the CDC/NCHS is considering a new ICD-10-CM diagnosis code for positive EsoGuard results. These administrative milestones are intended to streamline billing, coding, and physician reporting for the company's esophageal cancer screening tools.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.